Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine in Individuals With Rett Syndrome
NCT07640503Phase 2Enrolling by invitation
- Sponsor
- Maria Denise Fernandes Carvalho de Andrade
- Start
- Nov 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lamivudine in Rett syndrome (RTT), sponsored by Maria Denise Fernandes Carvalho de Andrade. Primary endpoints: Rett Syndrome Symptom Severity at Week 52, Rett Syndrome Behavioral Symptoms at Week 52 and 1 more. Started Nov 2025; status: enrolling by invitation.
02
Drugs
lamivudine
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT07640503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07640503.